Heme oxygenase-1 and iron in liver inflammation: A complex alliance

Current Drug Targets

Volumn 11, Issue 12, 2010, Pages 1541-1550

  Immenschuh, Stephan ^a   Baumgart Vogt, Eveline ^b   Mueller, Sebastian ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antioxidant; Heme oxygenase 1; Hepcidin; Inflammation; Iron; Liver; Oxidative stress

Indexed keywords

AMINOETHYLBENZENSULFONYL FLUORIDE; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; CURCUMIN; GINKGO BILOBA EXTRACT; HEME OXYGENASE 1; HEPCIDIN; IRON; IRON REGULATORY PROTEIN 1; MICRORNA; PEGINTERFERON; PENTOXIFYLLINE; POLYPHENOL; RIBAVIRIN; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ENZYME MECHANISM; ERYTHROPHAGOCYTOSIS; FENTON REACTION; HEPATITIS; HEPATITIS C; HOMEOSTASIS; HUMAN; IRON METABOLISM; IRON TRANSPORT; LIPID PEROXIDATION; LIVER PROTECTION; MACROPHAGE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; VIRUS HEPATITIS; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; ENZYME INDUCTION; ERYTHROCYTE; GENE THERAPY; GENETICS; KUPFFER CELL; LIVER; METABOLISM; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOPHAGOCYTOSIS; ENZYME INDUCTION; ERYTHROCYTES; GENE THERAPY; HEME OXYGENASE-1; HEPATITIS; HOMEOSTASIS; HUMANS; IRON; KUPFFER CELLS; LIVER;

EID: 78149428559     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111009011541     Document Type: Review

References (131)

1. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968; 61: 748-55.
2. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 1997; 37: 517-54.
3. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86: 583-650.
4. Kapitulnik J, Maines MD. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol Sci 2009; 30: 129-37.
5. Trakshel GM, Kutty RK, Maines MD. Purification and characterization of the major constitutive form of testicular heme oxygenase. The noninducible isoform. J Biol Chem 1986 25; 261: 11131-7.
6. Choi AMK, Alam J. Heme oxygenase-1: Function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 1996; 15: 9-19.
7. Immenschuh S, Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol 2000; 60: 1121-8.
8. Keyse SM, Applegate LA, Tromvoukis Y, Tyrrell RM. Oxidant stress leads to transcriptional activation of the human heme oxygenase gene in cultured skin fibroblasts. Mol Cell Biol 1990; 10: 4967-9.
9. Vile GF, Basu-Modak S, Waltner C, Tyrrell RM. Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci USA 1994 29; 91: 2607-10.
10. Otterbein LE, Choi AM. Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1029-37.
11. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 2010; 50: 323-54.
12. Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA 1997; 94: 10925-30.
13. Poss KD, Tonegawa S. Heme oxygenase is required for mammalian iron reutilization. Proc Natl Acad Sci USA 1997; 94: 10919-24.
14. Yachie A, Niida Y, Wada T, et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenasedeficiency. J Clin Invest 1999; 103: 129-35.
15. Kawashima A, Oda Y, Yachie A, Koizumi S, Nakanishi I. Heme oxygenase-1 deficiency: the first autopsy case. Hum Pathol 2002; 33: 125-30.
16. Burnett AL, Johns DG, Kriegsfeld LJ, et al. Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2. Nat Med 1998; 4: 84-7.
17. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004 30; 117: 285-97.
18. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005 15; 202: 199-211.
19. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256-62.
20. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341:1986-95.
21. Rothenberger S, Mullner EW, Kuhn LC. The mRNA-binding protein which controls ferritin and transferrin receptor expression is conserved during evolution. Nucleic Acids Res 1990; 18: 1175-9.
22. Beinert H, Holm RH, Munck E. Iron-sulfur clusters: nature's modular, multipurpose structures. Science 1997; 277: 653-9.
23. Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Curr Top Cell Regul 1997; 35: 1-19.
24. Campanella A, Levi S, Cairo G, Biasiotto G, Arosio P. Blotting analysis of native IRP1: a novel approach to distinguish the different forms of IRP1 in cells and tissues. Biochemistry 2004; 43: 195-204.
25. Narahari J, Ma R, Wang M, Walden WE. The aconitase function of iron regulatory protein 1. Genetic studies in yeast implicate its role in iron-mediated redox regulation. J Biol Chem 2000 26; 275: 16227-34.
26. Mueller S, Pantopoulos K. Activation of iron regulatory protein-1 (IRP1) by oxidative stress. Methods Enzymol 2002; 348: 324-37.
27. Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 2004; 1012: 1-13.
28. Mueller S, Pantopoulos K, Hübner CA, Stremmel W, Hentze MW. IRP1 activation by extracellular oxidative stress in the perfused rat liver. J Biol Chem 2001; 276: 23192-6.
29. Pantopoulos K, Mueller S, Atzberger A, Ansorge W, Stremmel W, Hentze MW. Differences in the regulation of IRP-1 (iron regulatory protein-1) by extra-and intracelullar oxidative stress. J Biol Chem 1997; 272: 9802-8.
30. Mütze S, Hebling U, Stremmel W, et al. Myeloperoxidase-derived hypochlorous acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 1. J Biol Chem 2003; 278: 40542-9.
31. Pantopoulos K, Weiss G, Hentze MW. Nitric oxide and oxidative stress (H2O2) control mammalian iron metabolism by different pathways. Mol Cell Biol 1996; 16: 3781-8.
32. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-6.
33. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is upregulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci USA 2005; 102: 1324-8.
34. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006; 26: 323-42.
35. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-9.
36. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
37. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-44.
38. Gehrke SG, Kulaksiz H, Herrmann T, et al. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrinbound iron. Blood 2003; 102: 371-6.
39. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003; 361: 669-73.
40. Kartikasari AE, Wagener FA, Yachie A, Wiegerinck ET, Kemna EH, Winkels DW. Hepcidin suppression and defective iron recycling account for dysregulation of iron homeostasis in heme oxygenase-1 deficiency. J Cell Mol Med 2009; 13: 3091-102.
41. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-8.
42. Mueller S, Afdhal NH, Schuppan D. Iron, HCV, and liver cancer: hard metal setting the pace? Gastroenterology 2006; 130: 2229-34.
43. Haque S, Chandra B, Gerber MA, Lok AS. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum Pathol 1996; 27: 1277-81.
44. Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003;30: 137-44.
45. Konijn AM. Iron metabolism in inflammation. Baillieres Clin Haematol 1994; 7: 829-49.
46. Roy CN, Custodio AO, de Graaf J, et al. An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. Nat Genet 2004; 36: 481-5.
47. Soe-Lin S, Sheftel AD, Wasyluk B, Ponka P. Nramp1 equips macrophages for efficient iron recycling. Exp Hematol 2008; 36: 929-37.
48. Eisenstein RS, Garcia-Mayol D, Pettingell W, Munro HN. Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron. Proc Natl Acad Sci USA 1991; 88: 688-92.
49. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 1992; 267: 18148-53.
50. Vile GF, Tyrrell RM. Oxidative stress resulting from ultraviolet A irradiation of human skin fibroblasts leads to a heme oxygenasedependent increase in ferritin. J Biol Chem 1993; 268: 14678-81.
51. Knutson MD, Vafa MR, Haile DJ, Wessling-Resnick M. Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. Blood 2003; 102: 4191-7.
52. Delaby C, Pilard N, Puy H, Canonne-Hergaux F. Sequential regulation of ferroportin expression after erythrophagocytosis in murine macrophages: early mRNA induction by haem, followed by iron-dependent protein expression. Biochem J 2008; 411: 123-31.
53. Marro S, Chiabrando D, Messana E, et al. Heme controls ferroportin 1(FPN1) transcription involving Bach1, Nrf2 and MARE/ARE sequence motif at position-7007 of the FPN1 promoter. Haematologica 2010; 95: 1261-8.
54. Kondo H, Saito K, Grasso JP, Aisen P. Iron metabolism in the erythrophagocytosing Kupffer cell. Hepatology 1988; 8: 32-8.
55. Dennery PA, Spitz DR, Yang G, et al. Oxygen toxicity and iron accumulation in the lungs of mice lacking heme oxygenase-2. J Clin Invest 1998; 101: 1001-11.
56. True AL, Olive M, Boehm M, et al. Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. Circ Res 2007; 101: 893-901.
57. Dennery PA, Visner G, Weng YH, et al. Resistance to hyperoxia with heme oxygenase-1 disruption: role of iron. Free Radic Biol Med 2003; 34: 124-33.
58. Tzima S, Victoratos P, Kranidioti K, Alexiou M, Kollias G. Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. J Exp Med 2009; 206: 1167-79.
59. Bauer I, Wanner GA, Rensing H, et al. Expression pattern of heme oxygenase isoenzymes 1 and 2 in normal and stress-exposed rat liver. Hepatology 1998; 27: 829-38.
60. Immenschuh S, Tan M, Ramadori G. Nitric oxide mediates the lipopolysaccharide dependent upregulation of the heme oxygenase-1 gene expression in cultured rat Kupffer cells. J Hepatol 1999;30: 61-9.
61. Wagener FA, Volk HD, Willis D, et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev 2003; 55: 551-71.
62. Wijayanti N, Katz N, Immenschuh S. Biology of heme in health and disease. Curr Med Chem 2004; 11: 981-6.
63. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis 2007; 27: 339-50.
64. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol 2002; 283: G256-65.
65. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006; 43: S54-62.
66. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009; 36: 4-12.
67. Lee TS, Chau LY. Heme oxygenase-1 mediates the antiinflammatory effect of interleukin-10 in mice. Nat Med 2002; 8: 240-6.
68. Kapturczak MH, Wasserfall C, Brusko T, et al. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am J Pathol 2004; 165: 1045-53.
69. Alam J, Cook JL. How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol 2007; 36: 166-74.
70. Thimmulappa RK, Lee H, Rangasamy T, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006; 116: 984-95.
71. Liu H, Dinkova-Kostova AT, Talalay P. Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci USA 2008; 105: 15926-31.
72. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.
73. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant response elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76-86.
74. Kobayashi M, Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 2005; 7: 385-94.
75. Komatsu M, Kurokawa H, Waguri S, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 2010; 12: 213-23.
76. Cable EE, Pepe JA, Karamtsios NC, Lambrecht RW, Bonkovsky HL. Differential effects of metalloporphyrins on messenger RNA levels of d-aminolevulinate synthase and heme oxygenase. J Clin Invest 1994; 94: 649-54.
77. Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 2004; 37: 2064-2071.
78. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006; 72: 1439-52.
79. Mann GE, Rowlands DJ, Li FY, de Winter P, Siow RC. Activation of endothelial nitric oxide synthase by dietary isoflavones: role of NO in Nrf2-mediated antioxidant gene expression. Cardiovasc Res 2007; 75: 261-74.
80. Yao P, Nussler A, Liu L, et al. Quercetin protects human hepatocytes from ethanol-derived oxidative stress by inducing heme oxygenase-1 via the MAPK/Nrf2 pathways. J Hepatol 2007; 47: 253-61.
81. Yao P, Hao L, Nussler N, et al. The protective role of HO-1 and its generated products (CO, bilirubin, and Fe) in ethanol-induced human hepatocyte damage. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1318-23.
82. Immenschuh S, Hinke V, Ohlmann A, Gifhorn-Katz S, Katz N, Jungermann K, Kietzmann T. Transcriptional activation of the haem oxygenase-1 gene by cGMP via a cAMP response element/activator protein-1 element in primary cultures of rat hepatocytes. Biochem J 1998; 334: 141-6.
83. Immenschuh S, Kietzmann T, Hinke V, Wiederhold M, Katz N, Muller-Eberhard U. The rat heme oxygenase-1 gene is transcriptionally induced via the protein kinase A signaling pathway in rat hepatocyte cultures. Mol Pharmacol 1998; 53: 483-91.
84. Mandal P, Park PH, McMullen MR, Pratt BT, Nagy LE. The antiinflammatory effects of adiponectin are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology 2010; 51: 1420-9.
85. Kiemer AK, Gerwig T, Gerbes AL, Meissner H, Bilzer M, Vollmar AM. Kupffer-cell specific induction of heme oxygenase 1 (hsp32) by the atrial natriuretic peptide--role of cGMP. J Hepatol; 38: 490-8.
86. Wijayanti N, Kietzmann T, Immenschuh S. Heme oxygenase-1 gene activation by the NAD(P)H oxidase inhibitor 4-(2-aminoethyl) benzenesulfonyl fluoride via a protein kinase B, p38-dependent signaling pathway in monocytes. J Biol Chem 2005; 280: 21820-9.
87. Kerr TA, Davidson NO. Therapeutic RNA manipulation in liver disease. Hepatology 2010; 51: 1055-61.
88. Amersi F, Buelow R, Kato H, et al. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Invest 1999; 104: 1631-9.
89. Zhu Z, Wilson AT, Mathahs MM, et al. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 2008; 48: 1430-9.
90. Shan Y, Zheng J, Lambrecht RW, Bonkovsky HL. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology 2007; 133: 1166-74.
91. Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010; 51: 1494-504.
92. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-100.
93. Sallie R, Di Bisceglie AM. Viral hepatitis and hepatocellular carcinoma. Gastroenterol Clin North Am 1994; 23: 567-79.
94. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21-9.
95. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol 2009; 15: 3462-71.
96. Protzer U, Seyfried S, Quasdorff M, et al. Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Gastroenterology 2007; 133: 1156-65.
97. Abdalla MY, Ahmad IM, Spitz DR, Schmidt WN, Britigan BE. Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses. J Med Virol 2005; 76: 489-97.
98. Abdalla MY, Britigan BE, Wen F, et al. Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. J Infect Dis 2004; 190: 1109-18.
99. Ghaziani T, Shan Y, Lambrecht RW, et al. HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. J Hepatol 2006; 45: 5-12.
100. Lehmann E, El-Tantawy WH, Ocker M, et al. The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology 2010; 51: 398-404.
101. Seitz HK, Mueller S. Alcoholic liver disease. In: Dancygier H, editor. Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. Heidelberg: Springer; 2009. pp. 1111-52.
102. McCullough AJ, O'Connor JFB. Alcoholic liver disease: proposed recommendationss for the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2022-36.
103. Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-5.
104. Seitz HK, Suter P. Ethanol toxicity and nutritional status. In: Kotsonis F, Mackey M, Eds. Nutritional Toxicology. 2nd ed. London. New York: Taylor and Francis; 2002. pp. 122-54.
105. Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998; 275: G605-11.
106. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.
107. Kishore R, McMullen MR, Nagy LE. Stabilization of tumor necrosis factor alpha mRNA by chronic ethanol: role of A + U-rich elements and p38 mitogen-activated protein kinase signaling pathway. J Biol Chem 2001; 276: 41930-7.
108. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003; 15: 247-54.
109. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
110. You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 2005; 42: 568-77.
111. Thakur V, Pritchard MT, McMullen MR, Nagy LE. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol 2006; 290: G998-1007.
112. Tsukamoto H, Lin M, Ohata M, Giulivi C, French SW, Brittenham G. Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am J Physiol 1999; 277: G1240-50.
113. Romics L, Jr., Mandrekar P, Kodys K, et al. Increased lipopolysaccharide sensitivity in alcoholic fatty livers is independent of leptin deficiency and toll-like receptor 4 (TLR4) or TLR2 mRNA expression. Alcohol Clin Exp Res 2005; 29: 1018-26.
114. Yao P, Li K, Song F, et al. Heme oxygenase-1 upregulated by Ginkgo biloba extract: potential protection against ethanol-induced oxidative liver damage. Food Chem Toxicol 2007; 45: 1333-42.
115. Bao W, Li K, Rong S, et al. Curcumin alleviates ethanol-induced hepatocytes oxidative damage involving heme oxygenase-1 induction. J Ethnopharmacol 2010; 128: 549-53.
116. Mandal P, Park PH, McMullen MR, Pratt BT, Nagy LE. The antiinflammatory effects of adiponectin are mediated via a heme oxygenase-1-dependent pathway in rat Kupffer cells. Hepatology 2010; 51: 1420-9.
117. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
118. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
119. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
120. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
121. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcoholinduced liver injury. Gastroenterology 1988; 95: 1056-62.
122. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
123. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
124. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996; 271: 665-8.
125. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002; 35: 497-9.
126. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
127. Senti M, Tomas M, Fito M, et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003; 88: 5422-6.
128. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 2005; 42: 585-91.
129. Ahmed U, Redgrave TG, Oates PS. Effect of dietary fat to produce non-alcoholic fatty liver in the rat. J Gastroenterol Hepatol 2009; 24: 1463-71.
130. Yu J, Chu ES, Wang R, et al. Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. Gastroenterology 2010; 138: 694-704.
131. Chowdhry S, Nazmy MH, Meakin PJ, et al. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 2010; 48: 357-71.